Lyda Osorio: Difference between revisions

Edit links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
consistent citation formatting
Line 13: Line 13:
== Education ==
== Education ==


Osorio studied medicine at the [[University of Caldas|Universidad de Caldas]].<ref name=":0" /> She then went on to do her 'mandatory social service' at CIDEIM<ref name=":2" /> for the final part of her medical degree. Osorio was awarded a scholarship from [[Administrative Department of Science, Technology and Innovation|Colciencias]] (Colombian government) to pursue a PhD in Epidemiology at the [[London School of Hygiene & Tropical Medicine|London School of Hygiene and Tropical Medicine]].<ref name=":3">{{Cite web|title=TDR {{!}} Dr Lyda Osorio, Colombia|url=http://www.who.int/tdr/news/2016/Lyda-Osorio/en/|access-date=2021-04-06|website=WHO}}</ref> She graduated in 2003, with a doctoral thesis on the effects of [[Internally displaced person|human movement]] on the transmission of malaria in the Colombian city of [[Quibdó]], which is [[Endemic (epidemiology)|endemic]] for ''[[Plasmodium falciparum]]'' and ''[[Plasmodium vivax|P. vivax]]''.<ref>{{Cite thesis|title=Effects of mobility on the transmission of malaria in an urban area in Colombia|url=https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.407523|publisher=London School of Hygiene and Tropical Medicine (University of London)|date=2003|degree=Ph.D.|first=Lyda Elena|last=Osorio-Amaya}}</ref><ref>{{Cite journal|last=Osorio|first=Lyda|last2=Todd|first2=Jim|last3=Bradley|first3=David J.|date=2004-10-01|title=TRAVEL HISTORIES AS RISK FACTORS IN THE ANALYSIS OF URBAN MALARIA IN COLOMBIA|url=https://www.ajtmh.org/view/journals/tpmd/71/4/article-p380.xml|journal=The American Journal of Tropical Medicine and Hygiene|language=en|volume=71|issue=4|pages=380–386|doi=10.4269/ajtmh.2004.71.380}}</ref><ref>{{Cite journal|last=Osorio|first=Lyda|last2=Todd|first2=Jim|last3=Bradley|first3=David|date=2004-03-01|title=Absence of asymptomatic malaria in schoolchildren of Quibdó, Chocó.|url=https://revistabiomedica.org/index.php/biomedica/article/view/1244|journal=Biomédica|language=en|volume=24|issue=1|pages=13–9|doi=10.7705/biomedica.v24i1.1244|issn=2590-7379}}</ref>
Osorio studied medicine at the [[University of Caldas|Universidad de Caldas]].<ref name=":0" /> She then went on to do her 'mandatory social service' at CIDEIM<ref name=":2" /> for the final part of her medical degree. Osorio was awarded a scholarship from [[Administrative Department of Science, Technology and Innovation|Colciencias]] (Colombian government) to pursue a PhD in Epidemiology at the [[London School of Hygiene & Tropical Medicine|London School of Hygiene and Tropical Medicine]].<ref name=":3">{{Cite web|title=TDR {{!}} Dr Lyda Osorio, Colombia|url=http://www.who.int/tdr/news/2016/Lyda-Osorio/en/|access-date=2021-04-06|website=WHO}}</ref> She graduated in 2003, with a doctoral thesis on the effects of [[Internally displaced person|human movement]] on the transmission of malaria in the Colombian city of [[Quibdó]], which is [[Endemic (epidemiology)|endemic]] for ''[[Plasmodium falciparum]]'' and ''[[Plasmodium vivax|P. vivax]]''.<ref>{{Cite thesis|title=Effects of mobility on the transmission of malaria in an urban area in Colombia|url=https://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.407523|publisher=London School of Hygiene and Tropical Medicine (University of London)|date=2003 | vauthors = Osorio-Amaya LE }}</ref><ref name="pmid15516630">{{cite journal | vauthors = Osorio L, Todd J, Bradley DJ | title = Travel histories as risk factors in the analysis of urban malaria in Colombia | journal = The American Journal of Tropical Medicine and Hygiene | volume = 71 | issue = 4 | pages = 380–6 | date = October 2004 | pmid = 15516630 | doi = 10.4269/ajtmh.2004.71.380 }}</ref><ref name="pmid15239597">{{cite journal | vauthors = Osorio L, Todd J, Bradley D | title = [Absence of asymptomatic malaria in schoolchildren of Quibdó, Chocó] | language = Spanish; Castilian | journal = Biomedica : Revista Del Instituto Nacional De Salud | volume = 24 | issue = 1 | pages = 13–9 | date = March 2004 | pmid = 15239597 | doi = | url = }}</ref>


== Career ==
== Career ==
Line 19: Line 19:
Osorio became an associate professor at the School of Public Health of the Universidad del Valle (UVAL) in 2007.<ref name=":1">{{Cite web|title=TDR Bio - Dr Lyda Osorio - Amaya|url=https://profiles.tdr-global.net/Lyda.Osorio.-.Amaya/about|url-status=live|access-date=2021-04-06|website=profiles.tdr-global.net}}</ref><ref name=":0" /> Between 2014 and 2016, Osorio acted as the director of postgraduate programmes, and in 2018 she became the coordinator of the MSc epidemiology program, at the same University.<ref name=":1" /> She conducts research at the Epidemiology and Population Health group at UVAL,<ref>{{Cite web|date=2019|title=Facultad de Salud|url=https://salud.univalle.edu.co/posgrados/doctorados/doctorado-en-salud|url-status=live|access-date=7 April 2021|website=Universidad del Valle}}</ref> and is an associated researcher with CIDEIM.<ref name=":0" /><ref>{{Cite web|title=CvLAC - RG|url=https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000043559|access-date=2021-04-08|website=scienti.minciencias.gov.co|language=en}}</ref>
Osorio became an associate professor at the School of Public Health of the Universidad del Valle (UVAL) in 2007.<ref name=":1">{{Cite web|title=TDR Bio - Dr Lyda Osorio - Amaya|url=https://profiles.tdr-global.net/Lyda.Osorio.-.Amaya/about|url-status=live|access-date=2021-04-06|website=profiles.tdr-global.net}}</ref><ref name=":0" /> Between 2014 and 2016, Osorio acted as the director of postgraduate programmes, and in 2018 she became the coordinator of the MSc epidemiology program, at the same University.<ref name=":1" /> She conducts research at the Epidemiology and Population Health group at UVAL,<ref>{{Cite web|date=2019|title=Facultad de Salud|url=https://salud.univalle.edu.co/posgrados/doctorados/doctorado-en-salud|url-status=live|access-date=7 April 2021|website=Universidad del Valle}}</ref> and is an associated researcher with CIDEIM.<ref name=":0" /><ref>{{Cite web|title=CvLAC - RG|url=https://scienti.minciencias.gov.co/cvlac/visualizador/generarCurriculoCv.do?cod_rh=0000043559|access-date=2021-04-08|website=scienti.minciencias.gov.co|language=en}}</ref>


In general her research has focused on the epidemiology, diagnosis and treatment of vector-borne diseases.<ref name=":3" /><ref>{{Cite journal|last=Osorio|first=Lyda|last2=Garcia|first2=Jonny Alejandro|last3=Parra|first3=Luis Gabriel|last4=Garcia|first4=Victor|last5=Torres|first5=Laura|last6=Degroote|first6=Stéphanie|last7=Ridde|first7=Valéry|date=2018-12-XX|title=A scoping review on the field validation and implementation of rapid diagnostic tests for vector-borne and other infectious diseases of poverty in urban areas|url=https://idpjournal.biomedcentral.com/articles/10.1186/s40249-018-0474-8|journal=Infectious Diseases of Poverty|language=en|volume=7|issue=1|pages=87|doi=10.1186/s40249-018-0474-8|issn=2049-9957|pmc=PMC6120097|pmid=30173662}}</ref> In 2013, Osorio applied for and won a [https://www.who.int/tdr/en/ WHO/TDR] fellowship to work at [[GlaxoSmithKline|GSK]]'s Diseases of the Developing World programme as a postdoctoral fellow.<ref name=":3" /> During her year at GSK she worked on a trial evaluating [[tafenoquine]] against ''P. vivax'' malaria, and on clinical data from a trial studying [[Glucose-6-phosphate dehydrogenase deficiency|G6PD deficiency]].<ref name=":3" /><ref>{{Cite web|last=Osorio|first=Lyda|title=What academics can learn from pharmaceutical clinical research: experiences from the WHO/TDR Fellowship|url=https://media.tghn.org/medialibrary/2014/07/LYDA_OSORIO_IDclinico_TDR_fellowship_june_2014.pdf|url-status=live|access-date=7 April 2021|website=TGHN|language=es}}</ref> Osorio is a Data Access Committee member of the [https://www.wwarn.org/ Worldwide Antimalarial Resistance Network] (WWARN).<ref>{{Cite web|date=2017-04-11|title=Dr Lyda Osorio|url=https://www.wwarn.org/about-us/governance-people/dr-lyda-osorio|access-date=2021-04-07|website=Worldwide Antimalarial Resistance Network|language=en}}</ref> As part of the WWARN's [[Malaria#Life cycle|gametocyte]] study group, she co-authored a meta-analysis of individual patient data to look at the effects of [[Antimalarial medication#Artemisinin-based combination therapies (ACTs)|artemisinin combination therapy]] in gametocyte carriage.<ref>{{Cite journal|last=WWARN Gametocyte Study Group|date=2016-05-24|title=Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data|url=https://doi.org/10.1186/s12916-016-0621-7|journal=BMC Medicine|volume=14|issue=1|pages=79|doi=10.1186/s12916-016-0621-7|issn=1741-7015|pmc=PMC4879753|pmid=27221542}}</ref>
In general her research has focused on the epidemiology, diagnosis and treatment of vector-borne diseases.<ref name=":3" /><ref>{{cite journal | vauthors = Osorio L, Garcia JA, Parra LG, Garcia V, Torres L, Degroote S, Ridde V | title = A scoping review on the field validation and implementation of rapid diagnostic tests for vector-borne and other infectious diseases of poverty in urban areas | journal = Infectious Diseases of Poverty | volume = 7 | issue = 1 | pages = 87 | date = September 2018 | pmid = 30173662 | pmc = 6120097 | doi = 10.1186/s40249-018-0474-8 }}</ref> In 2013, Osorio applied for and won a [https://www.who.int/tdr/en/ WHO/TDR] fellowship to work at [[GlaxoSmithKline|GSK]]'s Diseases of the Developing World programme as a postdoctoral fellow.<ref name=":3" /> During her year at GSK she worked on a trial evaluating [[tafenoquine]] against ''P. vivax'' malaria, and on clinical data from a trial studying [[Glucose-6-phosphate dehydrogenase deficiency|G6PD deficiency]].<ref name=":3" /><ref>{{Cite web| vauthors = Osorio L |title=What academics can learn from pharmaceutical clinical research: experiences from the WHO/TDR Fellowship|url=https://media.tghn.org/medialibrary/2014/07/LYDA_OSORIO_IDclinico_TDR_fellowship_june_2014.pdf|url-status=live|access-date=7 April 2021|website=TGHN|language=es}}</ref> Osorio is a Data Access Committee member of the [https://www.wwarn.org/ Worldwide Antimalarial Resistance Network] (WWARN).<ref>{{Cite web|date=2017-04-11|title=Dr Lyda Osorio|url=https://www.wwarn.org/about-us/governance-people/dr-lyda-osorio|access-date=2021-04-07|website=Worldwide Antimalarial Resistance Network|language=en}}</ref> As part of the WWARN's [[Malaria#Life cycle|gametocyte]] study group, she co-authored a meta-analysis of individual patient data to look at the effects of [[Antimalarial medication#Artemisinin-based combination therapies (ACTs)|artemisinin combination therapy]] in gametocyte carriage.<ref>{{cite journal | vauthors = | title = Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data | journal = BMC Medicine | volume = 14 | issue = 1 | pages = 79 | date = May 2016 | pmid = 27221542 | pmc = 4879753 | doi = 10.1186/s12916-016-0621-7 }}</ref>


In 2016, Osorio co-led a multi-center [[Case–control study|case-control study]] called Neurovirus Emerging in the Americas Study (NEAS), sponsored by [[Johns Hopkins University]], which aimed to characterize the development of neurological symptoms after exposure to dengue, [[chikungunya]] and Zika.<ref>{{Cite web|title=Clinical Trial on Encephalitis - Clinical Trials Registry - ICH GCP|url=https://ichgcp.net/clinical-trials-registry/NCT03206541|access-date=2021-04-07|website=ichgcp.net}}</ref><ref>{{Cite web|last=Colombia|first=Universidad Cooperativa de|title=Noticias UCC|url=https://www.ucc.edu.co:443/noticias/prensa/Paginas/CatalogItem-Prensa.aspx?TermStoreId=da8489ba-c815-42d8-af38-471476d1c4fc&TermSetId=06ca2747-e484-4935-a8d6-0bd8b1c11474&TermId=5d285473-a258-4f6e-8bc3-3a559a071e67&UrlSuffix=neurovirus-emergentes-de-las-americas|access-date=2021-04-07|website=www.ucc.edu.co|language=es-ES}}</ref> Results from this clinical trial supported the suspected development [[Guillain–Barré syndrome]] as a consequence of infection with the Zika virus.<ref>{{Cite journal|last=Parra|first=Beatriz|last2=Lizarazo|first2=Jairo|last3=Jiménez-Arango|first3=Jorge A.|last4=Zea-Vera|first4=Andrés F.|last5=González-Manrique|first5=Guillermo|last6=Vargas|first6=José|last7=Angarita|first7=Jorge A.|last8=Zuñiga|first8=Gonzalo|last9=Lopez-Gonzalez|first9=Reydmar|last10=Beltran|first10=Cindy L.|last11=Rizcala|first11=Karen H.|date=2016-10-20|title=Guillain–Barré Syndrome Associated with Zika Virus Infection in Colombia|url=https://doi.org/10.1056/NEJMoa1605564|journal=New England Journal of Medicine|volume=375|issue=16|pages=1513–1523|doi=10.1056/NEJMoa1605564|issn=0028-4793|pmid=27705091}}</ref> Osorio's further work in Zika has included the evaluation of personal protection measures by pregnant women and women of reproductive age in Colombia against the ''[[Aedes]]'' mosquito vector.<ref>{{Cite journal|last=Mendoza|first=Carolina|last2=Jaramillo|first2=Gloria-Isabel|last3=Ant|first3=Thomas H.|last4=Power|first4=Grace M.|last5=Jones|first5=Robert T.|last6=Quintero|first6=Juliana|last7=Alexander|first7=Neal|last8=Webster|first8=Jayne|last9=Osorio|first9=Lyda|last10=Logan|first10=James G.|date=2020-01-21|title=An investigation into the knowledge, perceptions and role of personal protective technologies in Zika prevention in Colombia|url=https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0007970|journal=PLOS Neglected Tropical Diseases|language=en|volume=14|issue=1|pages=e0007970|doi=10.1371/journal.pntd.0007970|issn=1935-2735|pmc=PMC7010294|pmid=31961867}}</ref> She has also worked with dengue diagnosis in Colombia,<ref>{{Cite journal|last=Caicedo-Borrero|first=Diana María|last2=Tovar|first2=José Rafael|last3=Méndez|first3=Andrés|last4=Parra|first4=Beatriz|last5=Bonelo|first5=Anilza|last6=Celis|first6=Jairo|last7=Villegas|first7=Liliana|last8=Collazos|first8=Constanza|last9=Osorio|first9=Lyda|date=2020-06-03|title=Development and Performance of Dengue Diagnostic Clinical Algorithms in Colombia|url=https://ajtmh.org/doi/10.4269/ajtmh.19-0722|journal=The American Journal of Tropical Medicine and Hygiene|language=en|volume=102|issue=6|pages=1226–1236|doi=10.4269/ajtmh.19-0722|issn=0002-9637|pmc=PMC7253082|pmid=32342839}}</ref><ref>{{Cite journal|last=Tello-Cajiao|first=María Elena|last2=Osorio|first2=Lyda|date=2019-09-04|title=Impact of Dengue Rapid Diagnostic Tests on the Prescription of Antibiotics and Anti-Inflammatory Drugs by Physicians in an Endemic Area in Colombia|url=https://www.ajtmh.org/view/journals/tpmd/101/3/article-p696.xml|journal=The American Journal of Tropical Medicine and Hygiene|language=EN|volume=101|issue=3|pages=696–704|doi=10.4269/ajtmh.19-0222|issn=0002-9637|pmc=PMC6726934|pmid=31333163}}</ref><ref>{{Cite journal|last=Osorio|first=Lyda|last2=Uribe|first2=Marcela|last3=Ardila|first3=Gloria Ines|last4=Orejuela|first4=Yaneth|last5=Velasco|first5=Margarita|last6=Bonelo|first6=Anilza|last7=Parra|first7=Beatriz|date=2015-05-15|title=The use of rapid dengue diagnostic tests in a routine clinical setting in a dengue-endemic area of Colombia|url=http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762015000400510&lng=en&tlng=en|journal=Memórias do Instituto Oswaldo Cruz|volume=110|issue=4|pages=510–516|doi=10.1590/0074-02760140359|issn=1678-8060|pmc=PMC4501415|pmid=25993399}}</ref> and participated in clinical trials evaluating the use of [[meglumine antimoniate]] versus [[miltefosine]] for the treatment of [[cutaneous leishmaniasis]] in adults and children.<ref>{{Cite journal|last=Castro|first=Maria del Mar|last2=Cossio|first2=Alexandra|last3=Velasco|first3=Carlos|last4=Osorio|first4=Lyda|date=2017-04-05|title=Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study|url=https://journals.plos.org/plosntds/article?id=10.1371/journal.pntd.0005515|journal=PLOS Neglected Tropical Diseases|language=en|volume=11|issue=4|pages=e0005515|doi=10.1371/journal.pntd.0005515|issn=1935-2735|pmc=PMC5393627|pmid=28379954}}</ref><ref>{{Cite journal|last=Rubiano|first=Luisa Consuelo|last2=Miranda|first2=María Consuelo|last3=Muvdi Arenas|first3=Sandra|last4=Montero|first4=Luz Mery|last5=Rodríguez-Barraquer|first5=Isabel|last6=Garcerant|first6=Daniel|last7=Prager|first7=Martín|last8=Osorio|first8=Lyda|last9=Rojas|first9=Maria Ximena|last10=Pérez|first10=Mauricio|last11=Nicholls|first11=Ruben Santiago|date=2012-02-15|title=Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children|url=https://doi.org/10.1093/infdis/jir816|journal=The Journal of Infectious Diseases|volume=205|issue=4|pages=684–692|doi=10.1093/infdis/jir816|issn=0022-1899|pmc=PMC3266136|pmid=22238470}}</ref>
In 2016, Osorio co-led a multi-center [[Case–control study|case-control study]] called Neurovirus Emerging in the Americas Study (NEAS), sponsored by [[Johns Hopkins University]], which aimed to characterize the development of neurological symptoms after exposure to dengue, [[chikungunya]] and Zika.<ref>{{Cite web|title=Clinical Trial on Encephalitis - Clinical Trials Registry - ICH GCP|url=https://ichgcp.net/clinical-trials-registry/NCT03206541|access-date=2021-04-07|website=ichgcp.net}}</ref><ref>{{cite web | author = Universidad Cooperativa de Colombia |title=Noticias UCC|url=https://www.ucc.edu.co:443/noticias/prensa/Paginas/CatalogItem-Prensa.aspx?TermStoreId=da8489ba-c815-42d8-af38-471476d1c4fc&TermSetId=06ca2747-e484-4935-a8d6-0bd8b1c11474&TermId=5d285473-a258-4f6e-8bc3-3a559a071e67&UrlSuffix=neurovirus-emergentes-de-las-americas|access-date=2021-04-07|website=www.ucc.edu.co|language=es-ES}}</ref> Results from this clinical trial supported the suspected development [[Guillain–Barré syndrome]] as a consequence of infection with the Zika virus.<ref>{{cite journal | vauthors = Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, Angarita JA, Zuñiga G, Lopez-Gonzalez R, Beltran CL, Rizcala KH, Morales MT, Pacheco O, Ospina ML, Kumar A, Cornblath DR, Muñoz LS, Osorio L, Barreras P, Pardo CA | display-authors = 6 | title = Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia | journal = The New England Journal of Medicine | volume = 375 | issue = 16 | pages = 1513–1523 | date = October 2016 | pmid = 27705091 | doi = 10.1056/NEJMoa1605564 }}</ref> Osorio's further work in Zika has included the evaluation of personal protection measures by pregnant women and women of reproductive age in Colombia against the ''[[Aedes]]'' mosquito vector.<ref>{{cite journal | vauthors = Mendoza C, Jaramillo GI, Ant TH, Power GM, Jones RT, Quintero J, Alexander N, Webster J, Osorio L, Logan JG | display-authors = 6 | title = An investigation into the knowledge, perceptions and role of personal protective technologies in Zika prevention in Colombia | journal = PLoS Neglected Tropical Diseases | volume = 14 | issue = 1 | pages = e0007970 | date = January 2020 | pmid = 31961867 | pmc = 7010294 | doi = 10.1371/journal.pntd.0007970 }}</ref> She has also worked with dengue diagnosis in Colombia,<ref>{{cite journal | vauthors = Caicedo-Borrero DM, Tovar JR, Méndez A, Parra B, Bonelo A, Celis J, Villegas L, Collazos C, Osorio L | display-authors = 6 | title = Development and Performance of Dengue Diagnostic Clinical Algorithms in Colombia | journal = The American Journal of Tropical Medicine and Hygiene | volume = 102 | issue = 6 | pages = 1226–1236 | date = June 2020 | pmid = 32342839 | pmc = 7253082 | doi = 10.4269/ajtmh.19-0722 }}</ref><ref>{{cite journal | vauthors = Tello-Cajiao ME, Osorio L | title = Impact of Dengue Rapid Diagnostic Tests on the Prescription of Antibiotics and Anti-Inflammatory Drugs by Physicians in an Endemic Area in Colombia | language = EN | journal = The American Journal of Tropical Medicine and Hygiene | volume = 101 | issue = 3 | pages = 696–704 | date = September 2019 | pmid = 31333163 | pmc = 6726934 | doi = 10.4269/ajtmh.19-0222 }}</ref><ref>{{cite journal | vauthors = Osorio L, Uribe M, Ardila GI, Orejuela Y, Velasco M, Bonelo A, Parra B | title = The use of rapid dengue diagnostic tests in a routine clinical setting in a dengue-endemic area of Colombia | journal = Memorias Do Instituto Oswaldo Cruz | volume = 110 | issue = 4 | pages = 510–6 | date = June 2015 | pmid = 25993399 | pmc = 4501415 | doi = 10.1590/0074-02760140359 }}</ref> and participated in clinical trials evaluating the use of [[meglumine antimoniate]] versus [[miltefosine]] for the treatment of [[cutaneous leishmaniasis]] in adults and children.<ref>{{cite journal | vauthors = Castro MD, Cossio A, Velasco C, Osorio L | title = Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study | journal = PLoS Neglected Tropical Diseases | volume = 11 | issue = 4 | pages = e0005515 | date = April 2017 | pmid = 28379954 | pmc = 5393627 | doi = 10.1371/journal.pntd.0005515 }}</ref><ref>{{cite journal | vauthors = Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, Prager M, Osorio L, Rojas MX, Pérez M, Nicholls RS, Gore Saravia N | display-authors = 6 | title = Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children | journal = The Journal of Infectious Diseases | volume = 205 | issue = 4 | pages = 684–92 | date = February 2012 | pmid = 22238470 | pmc = 3266136 | doi = 10.1093/infdis/jir816 }}</ref>


==== Work during the COVID-19 pandemic ====
==== Work during the COVID-19 pandemic ====
Osorio has also played a role in Colombia's response against [[COVID-19 pandemic in Colombia|COVID-19]].<ref name=":2" /> She was designated by the mayor of Cali as the "city's epidemiologist" to help the local Health Department's planning of adequate measures against the pandemic.<ref name=":4">{{Cite web|title=Intervención interdisciplinaria desde la Salud Pública|url=https://comunicasalud.wixsite.com/comunicandosalud/intervencion-interdisciplinaria-cal|url-status=live|access-date=2021-04-07|website=Universidad del Valle|language=es}}</ref> Osorio is one of several scientists communicating with the Colombian government about strategies to control the spread of the new coronavirus,<ref>{{Cite web|date=2020|title=Variaciones territoriales de la curva Covid – 19 en Colombia: De la eco-epidemiologia a la antropología|url=https://www.minciencias.gov.co/sala_de_prensa/variaciones-territoriales-la-curva-covid-19-en-colombia-la-eco-epidemiologia-la|url-status=live|access-date=7 April 2021|website=MinCiencias Colombia|language=es}}</ref> including a request to support universities working on diagnosis and research.<ref>{{Cite web|last=Varela|first=Por: William|title=Científicos reunidos con senadores piden apoyar a universidades con equipos y personal para aumentar muestras de Covid-19|url=https://senado.gov.co/index.php/prensa/lista-de-noticias/1093-cientificos-reunidos-con-senadores-piden-apoyar-a-universidades-con-equipos-y-personal-para-aumentar-muestras-de-covid-19|access-date=2021-04-08|website=Senado de la República de Colombia|language=es-es}}</ref>
Osorio has also played a role in Colombia's response against [[COVID-19 pandemic in Colombia|COVID-19]].<ref name=":2" /> She was designated by the mayor of Cali as the "city's epidemiologist" to help the local Health Department's planning of adequate measures against the pandemic.<ref name=":4">{{Cite web|title=Intervención interdisciplinaria desde la Salud Pública|url=https://comunicasalud.wixsite.com/comunicandosalud/intervencion-interdisciplinaria-cal|url-status=live|access-date=2021-04-07|website=Universidad del Valle|language=es}}</ref> Osorio is one of several scientists communicating with the Colombian government about strategies to control the spread of the new coronavirus,<ref>{{Cite web|date=2020|title=Variaciones territoriales de la curva Covid – 19 en Colombia: De la eco-epidemiologia a la antropología|url=https://www.minciencias.gov.co/sala_de_prensa/variaciones-territoriales-la-curva-covid-19-en-colombia-la-eco-epidemiologia-la|url-status=live|access-date=7 April 2021|website=MinCiencias Colombia|language=es}}</ref> including a request to support universities working on diagnosis and research.<ref>{{Cite web| vauthors = Varela PW |title=Científicos reunidos con senadores piden apoyar a universidades con equipos y personal para aumentar muestras de Covid-19|url=https://senado.gov.co/index.php/prensa/lista-de-noticias/1093-cientificos-reunidos-con-senadores-piden-apoyar-a-universidades-con-equipos-y-personal-para-aumentar-muestras-de-covid-19|access-date=2021-04-08|website=Senado de la República de Colombia|language=es-es}}</ref>


==== Other appointments and activities ====
==== Other appointments and activities ====


* Osorio is a member of the ZikaPLAN Consortium, a network of researchers focused on Zika and other emerging infectious diseases<ref>{{Cite web|title=Consortium Members|url=https://zikaplan.tghn.org/about-zikaplan/consortium-members/|url-status=live|access-date=6 April 2021|website=ZikaPLAN}}</ref><ref>{{Cite journal|last=Wilder-Smith|first=Annelies|last2=Preet|first2=Raman|last3=Brickley|first3=Elizabeth B.|last4=Ximenes|first4=Ricardo Arraes de Alencar|last5=Miranda-Filho|first5=Demócrito de Barros|last6=Martelli|first6=Celina Maria Turchi|last7=Araújo|first7=Thália Velho Barreto de|last8=Montarroyos|first8=Ulisses Ramos|last9=Moreira|first9=Maria Elisabeth|last10=Turchi|first10=Marília Dalva|last11=Solomon|first11=Tom|date=2019-01-01|title=ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas|url=https://doi.org/10.1080/16549716.2019.1666566|journal=Global Health Action|volume=12|issue=1|pages=1666566|doi=10.1080/16549716.2019.1666566|issn=1654-9716|pmc=PMC6818126|pmid=31640505}}</ref>
* Osorio is a member of the ZikaPLAN Consortium, a network of researchers focused on Zika and other emerging infectious diseases<ref>{{Cite web|title=Consortium Members|url=https://zikaplan.tghn.org/about-zikaplan/consortium-members/|url-status=live|access-date=6 April 2021|website=ZikaPLAN}}</ref><ref>{{cite journal | vauthors = Wilder-Smith A, Preet R, Brickley EB, Ximenes RA, Miranda-Filho DB, Turchi Martelli CM, Araújo TV, Montarroyos UR, Moreira ME, Turchi MD, Solomon T, Jacobs BC, Villamizar CP, Osorio L, de Filipps AM, Neyts J, Kaptein S, Huits R, Ariën KK, Willison HJ, Edgar JM, Barnett SC, Peeling R, Boeras D, Guzman MG, de Silva AM, Falconar AK, Romero-Vivas C, Gaunt MW, Sette A, Weiskopf D, Lambrechts L, Dolk H, Morris JK, Orioli IM, O'Reilly KM, Yakob L, Rocklöv J, Soares C, Ferreira ML, Franca RF, Precioso AR, Logan J, Lang T, Jamieson N, Massad E | display-authors = 6 | title = ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas | journal = Global Health Action | volume = 12 | issue = 1 | pages = 1666566 | date = 2019-01-01 | pmid = 31640505 | pmc = 6818126 | doi = 10.1080/16549716.2019.1666566 }}</ref>
*Member of the [[Pan American Health Organization]] Malaria Technical Advisory Group.<ref>{{Cite web|last=|first=|last2=|date=2019-05-25|title=PAHO/WHO {{!}} Malaria Technical Advisory Group - Current Members|url=https://www.paho.org/hq/index.php?option=com_content&view=article&id=15208:malaria-technical-advisory-group-current-members&Itemid=40370&lang=en|url-status=live|access-date=2021-04-06|website=Pan American Health Organization / World Health Organization|language=en-us}}</ref>
*Member of the [[Pan American Health Organization]] Malaria Technical Advisory Group.<ref>{{Cite web |date=2019-05-25|title=PAHO/WHO {{!}} Malaria Technical Advisory Group - Current Members|url=https://www.paho.org/hq/index.php?option=com_content&view=article&id=15208:malaria-technical-advisory-group-current-members&Itemid=40370&lang=en|url-status=live|access-date=2021-04-06|website=Pan American Health Organization / World Health Organization|language=en-us}}</ref>
*Data Access Committee member for the Infectious Diseases Data Observatory (IDDO).<ref>{{Cite web|title=Dr Lyda Osorio {{!}} Infectious Diseases Data Observatory|url=https://www.iddo.org/iddo-dac/dr-lyda-osorio|access-date=2021-04-13|website=www.iddo.org}}</ref>
*Data Access Committee member for the Infectious Diseases Data Observatory (IDDO).<ref>{{Cite web|title=Dr Lyda Osorio {{!}} Infectious Diseases Data Observatory|url=https://www.iddo.org/iddo-dac/dr-lyda-osorio|access-date=2021-04-13|website=www.iddo.org}}</ref>
* Editorial advisory board member for [[The BMJ|BMJ Global Health]].<ref>{{Cite web|title=Editorial Board|url=http://gh.bmj.com/pages/editorial-board/|access-date=2021-04-06|website=BMJ Global Health|language=en}}</ref>
* Editorial advisory board member for [[The BMJ|BMJ Global Health]].<ref>{{Cite web|title=Editorial Board|url=http://gh.bmj.com/pages/editorial-board/|access-date=2021-04-06|website=BMJ Global Health|language=en}}</ref>
Line 47: Line 47:
*LE Osorio, CM Castillo, MT Ochoa. 1998. Mucosal leishmaniasis due to ''Leishmania'' (Viannia) ''panamensis'' in Colombia: clinical characteristics. ''Am J Trop Med Hyg''; 59(1):49-52. doi: [[doi:10.4269/ajtmh.1998.59.49|10.4269/ajtmh.1998.59.49]].
*LE Osorio, CM Castillo, MT Ochoa. 1998. Mucosal leishmaniasis due to ''Leishmania'' (Viannia) ''panamensis'' in Colombia: clinical characteristics. ''Am J Trop Med Hyg''; 59(1):49-52. doi: [[doi:10.4269/ajtmh.1998.59.49|10.4269/ajtmh.1998.59.49]].


==References==
== References ==
{{reflist}}
{{reflist}}


Revision as of 18:57, 15 April 2021

Lyda Osorio
NationalityColombian
Alma materUniversidad de Caldas (MD), London School of Hygiene and Tropical Medicine (PhD)
Scientific career
FieldsEpidemiology, Infectious disease, Vector-borne disease
InstitutionsUniversidad del Valle, CIDEIM
Thesis Effects of mobility on the transmission of malaria in an urban area in Colombia
Doctoral advisorProf. David Bradley

Lyda Elena Osorio Amaya is a Colombian physician, epidemiologist and infectious disease specialist.[1] She is an associate professor at the Universidad del Valle, and a researcher at the Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM) in Cali, Valle del Cauca.[1] Osorio's research has focused mainly on vector-borne diseases like malaria, leishmaniasis, Zika and dengue fever.[2] She has also played a role in Colombia's response against COVID-19.[3]

Education

Osorio studied medicine at the Universidad de Caldas.[1] She then went on to do her 'mandatory social service' at CIDEIM[4] for the final part of her medical degree. Osorio was awarded a scholarship from Colciencias (Colombian government) to pursue a PhD in Epidemiology at the London School of Hygiene and Tropical Medicine.[2] She graduated in 2003, with a doctoral thesis on the effects of human movement on the transmission of malaria in the Colombian city of Quibdó, which is endemic for Plasmodium falciparum and P. vivax.[5][6][7]

Career

Osorio became an associate professor at the School of Public Health of the Universidad del Valle (UVAL) in 2007.[8][1] Between 2014 and 2016, Osorio acted as the director of postgraduate programmes, and in 2018 she became the coordinator of the MSc epidemiology program, at the same University.[8] She conducts research at the Epidemiology and Population Health group at UVAL,[9] and is an associated researcher with CIDEIM.[1][10]

In general her research has focused on the epidemiology, diagnosis and treatment of vector-borne diseases.[2][11] In 2013, Osorio applied for and won a WHO/TDR fellowship to work at GSK's Diseases of the Developing World programme as a postdoctoral fellow.[2] During her year at GSK she worked on a trial evaluating tafenoquine against P. vivax malaria, and on clinical data from a trial studying G6PD deficiency.[2][12] Osorio is a Data Access Committee member of the Worldwide Antimalarial Resistance Network (WWARN).[13] As part of the WWARN's gametocyte study group, she co-authored a meta-analysis of individual patient data to look at the effects of artemisinin combination therapy in gametocyte carriage.[14]

In 2016, Osorio co-led a multi-center case-control study called Neurovirus Emerging in the Americas Study (NEAS), sponsored by Johns Hopkins University, which aimed to characterize the development of neurological symptoms after exposure to dengue, chikungunya and Zika.[15][16] Results from this clinical trial supported the suspected development Guillain–Barré syndrome as a consequence of infection with the Zika virus.[17] Osorio's further work in Zika has included the evaluation of personal protection measures by pregnant women and women of reproductive age in Colombia against the Aedes mosquito vector.[18] She has also worked with dengue diagnosis in Colombia,[19][20][21] and participated in clinical trials evaluating the use of meglumine antimoniate versus miltefosine for the treatment of cutaneous leishmaniasis in adults and children.[22][23]

Work during the COVID-19 pandemic

Osorio has also played a role in Colombia's response against COVID-19.[4] She was designated by the mayor of Cali as the "city's epidemiologist" to help the local Health Department's planning of adequate measures against the pandemic.[3] Osorio is one of several scientists communicating with the Colombian government about strategies to control the spread of the new coronavirus,[24] including a request to support universities working on diagnosis and research.[25]

Other appointments and activities

  • Osorio is a member of the ZikaPLAN Consortium, a network of researchers focused on Zika and other emerging infectious diseases[26][27]
  • Member of the Pan American Health Organization Malaria Technical Advisory Group.[28]
  • Data Access Committee member for the Infectious Diseases Data Observatory (IDDO).[29]
  • Editorial advisory board member for BMJ Global Health.[30]

Awards and recognitions

In December 2020, Osorio received the "Order ‘Confederate Cities’ in the rank of Commander Cross" on Pan American Doctor's day from the governor of Cali (Colombia) for her research and leadership during the COVID-19 pandemic in her country.[31]

For International Women's Day in 2021, Osorio was highlighted by the World Health Organization as an one of 15 influential women in science around the world; Osorio was featured for her work against infectious diseases, and her leadership during the COVID-19 pandemic in Colombia.[32][4]

Selected publications

  • Beatriz Parra, Jairo Lizarazo, Jorge A Jiménez-Arango, Andrés F Zea-Vera, Guillermo González-Manrique, José Vargas, Jorge A Angarita, Gonzalo Zuñiga, Reydmar Lopez-Gonzalez, Cindy L Beltran, Karen H Rizcala, Maria T Morales, Oscar Pacheco, Martha L Ospina, Anupama Kumar, David R Cornblath, Laura S Muñoz, Lyda Osorio, Paula Barreras, Carlos A Pardo. 2016. Guillain–Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med; 375:1513-1523. doi: 10.1056/NEJMoa1605564.
  • Kasia Stepniewska, Elizabeth Ashley, Sue J Lee, Nicholas Anstey, Karen I Barnes, Tran Quang Binh, Umberto D'Alessandro, Nicholas PJ Day, Peter J de Vries, Grant Dorsey, Jean-Paul Guthmann, Mayfong Mayxay, Paul N Newton, Piero Olliaro, Lyda Osorio, Ric N Price, Mark Rowland, Frank Smithuis, Walter RJ Taylor, François Nosten, Nicholas J White. 2010. In vivo parasitological measures of artemisinin susceptibility. J Infect Dis; 201(4):570-9. doi: 10.1086/650301.
  • Sara Schroter, Nick Black, Stephen Evans, Fiona Godlee, Lyda Osorio, Richard Smith. 2008. What errors do peer reviewers detect, and does training improve their ability to detect them? J R Soc Med;101(10):507-14. doi: 10.1258/jrsm.2008.080062.
  • Ricardo Palacios, Lyda Elena Osorio, LF Grajalew, Maria Teresa Ochoa. 2001. Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimoniate for cutaneous leishmaniasis due to Leishmania viannia species. Am J Trop Med Hyg; 64(3-4):187-93. doi: 10.4269/ajtmh.2001.64.187.
  • Lyda Osorio, Meleny Ramirez, Anilza Bonelo, Luis A Villar, Beatriz Parra. 2010. Comparison of the diagnostic accuracy of commercial NS1-based diagnostic tests for early dengue infection. Virol J; 7:361. doi: 10.1186/1743-422X-7-361.
  • LE Osorio, CM Castillo, MT Ochoa. 1998. Mucosal leishmaniasis due to Leishmania (Viannia) panamensis in Colombia: clinical characteristics. Am J Trop Med Hyg; 59(1):49-52. doi: 10.4269/ajtmh.1998.59.49.

References

  1. ^ a b c d e "Escuela de Salud Pública - Lyda Elena Osorio Amaya". Universidad del Valle (Colombia) (in Spanish). Retrieved 6 April 2021.{{cite web}}: CS1 maint: url-status (link)
  2. ^ a b c d e "TDR | Dr Lyda Osorio, Colombia". WHO. Retrieved 2021-04-06.
  3. ^ a b "Intervención interdisciplinaria desde la Salud Pública". Universidad del Valle (in Spanish). Retrieved 2021-04-07.{{cite web}}: CS1 maint: url-status (link)
  4. ^ a b c Women in science: a storytelling showcase. https://www.who.int/tdr/publications/women-in-science.pdf: World Health Organization. 2021. pp. 40–41. ISBN 978-92-4-002189-1. {{cite book}}: External link in |location= (help)
  5. ^ Osorio-Amaya LE (2003). Effects of mobility on the transmission of malaria in an urban area in Colombia (Thesis). London School of Hygiene and Tropical Medicine (University of London).
  6. ^ Osorio L, Todd J, Bradley DJ (October 2004). "Travel histories as risk factors in the analysis of urban malaria in Colombia". The American Journal of Tropical Medicine and Hygiene. 71 (4): 380–6. doi:10.4269/ajtmh.2004.71.380. PMID 15516630.
  7. ^ Osorio L, Todd J, Bradley D (March 2004). "[Absence of asymptomatic malaria in schoolchildren of Quibdó, Chocó]". Biomedica : Revista Del Instituto Nacional De Salud (in Spanish; Castilian). 24 (1): 13–9. PMID 15239597.{{cite journal}}: CS1 maint: unrecognized language (link)
  8. ^ a b "TDR Bio - Dr Lyda Osorio - Amaya". profiles.tdr-global.net. Retrieved 2021-04-06.{{cite web}}: CS1 maint: url-status (link)
  9. ^ "Facultad de Salud". Universidad del Valle. 2019. Retrieved 7 April 2021.{{cite web}}: CS1 maint: url-status (link)
  10. ^ "CvLAC - RG". scienti.minciencias.gov.co. Retrieved 2021-04-08.
  11. ^ Osorio L, Garcia JA, Parra LG, Garcia V, Torres L, Degroote S, Ridde V (September 2018). "A scoping review on the field validation and implementation of rapid diagnostic tests for vector-borne and other infectious diseases of poverty in urban areas". Infectious Diseases of Poverty. 7 (1): 87. doi:10.1186/s40249-018-0474-8. PMC 6120097. PMID 30173662.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  12. ^ Osorio L. "What academics can learn from pharmaceutical clinical research: experiences from the WHO/TDR Fellowship" (PDF). TGHN (in Spanish). Retrieved 7 April 2021.{{cite web}}: CS1 maint: url-status (link)
  13. ^ "Dr Lyda Osorio". Worldwide Antimalarial Resistance Network. 2017-04-11. Retrieved 2021-04-07.
  14. ^ "Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data". BMC Medicine. 14 (1): 79. May 2016. doi:10.1186/s12916-016-0621-7. PMC 4879753. PMID 27221542.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  15. ^ "Clinical Trial on Encephalitis - Clinical Trials Registry - ICH GCP". ichgcp.net. Retrieved 2021-04-07.
  16. ^ Universidad Cooperativa de Colombia. "Noticias UCC". www.ucc.edu.co (in European Spanish). Retrieved 2021-04-07.
  17. ^ Parra B, Lizarazo J, Jiménez-Arango JA, Zea-Vera AF, González-Manrique G, Vargas J, et al. (October 2016). "Guillain-Barré Syndrome Associated with Zika Virus Infection in Colombia". The New England Journal of Medicine. 375 (16): 1513–1523. doi:10.1056/NEJMoa1605564. PMID 27705091.
  18. ^ Mendoza C, Jaramillo GI, Ant TH, Power GM, Jones RT, Quintero J, et al. (January 2020). "An investigation into the knowledge, perceptions and role of personal protective technologies in Zika prevention in Colombia". PLoS Neglected Tropical Diseases. 14 (1): e0007970. doi:10.1371/journal.pntd.0007970. PMC 7010294. PMID 31961867.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  19. ^ Caicedo-Borrero DM, Tovar JR, Méndez A, Parra B, Bonelo A, Celis J, et al. (June 2020). "Development and Performance of Dengue Diagnostic Clinical Algorithms in Colombia". The American Journal of Tropical Medicine and Hygiene. 102 (6): 1226–1236. doi:10.4269/ajtmh.19-0722. PMC 7253082. PMID 32342839.
  20. ^ Tello-Cajiao ME, Osorio L (September 2019). "Impact of Dengue Rapid Diagnostic Tests on the Prescription of Antibiotics and Anti-Inflammatory Drugs by Physicians in an Endemic Area in Colombia". The American Journal of Tropical Medicine and Hygiene. 101 (3): 696–704. doi:10.4269/ajtmh.19-0222. PMC 6726934. PMID 31333163.
  21. ^ Osorio L, Uribe M, Ardila GI, Orejuela Y, Velasco M, Bonelo A, Parra B (June 2015). "The use of rapid dengue diagnostic tests in a routine clinical setting in a dengue-endemic area of Colombia". Memorias Do Instituto Oswaldo Cruz. 110 (4): 510–6. doi:10.1590/0074-02760140359. PMC 4501415. PMID 25993399.
  22. ^ Castro MD, Cossio A, Velasco C, Osorio L (April 2017). "Risk factors for therapeutic failure to meglumine antimoniate and miltefosine in adults and children with cutaneous leishmaniasis in Colombia: A cohort study". PLoS Neglected Tropical Diseases. 11 (4): e0005515. doi:10.1371/journal.pntd.0005515. PMC 5393627. PMID 28379954.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  23. ^ Rubiano LC, Miranda MC, Muvdi Arenas S, Montero LM, Rodríguez-Barraquer I, Garcerant D, et al. (February 2012). "Noninferiority of miltefosine versus meglumine antimoniate for cutaneous leishmaniasis in children". The Journal of Infectious Diseases. 205 (4): 684–92. doi:10.1093/infdis/jir816. PMC 3266136. PMID 22238470.
  24. ^ "Variaciones territoriales de la curva Covid – 19 en Colombia: De la eco-epidemiologia a la antropología". MinCiencias Colombia (in Spanish). 2020. Retrieved 7 April 2021.{{cite web}}: CS1 maint: url-status (link)
  25. ^ Varela PW. "Científicos reunidos con senadores piden apoyar a universidades con equipos y personal para aumentar muestras de Covid-19". Senado de la República de Colombia (in European Spanish). Retrieved 2021-04-08.
  26. ^ "Consortium Members". ZikaPLAN. Retrieved 6 April 2021.{{cite web}}: CS1 maint: url-status (link)
  27. ^ Wilder-Smith A, Preet R, Brickley EB, Ximenes RA, Miranda-Filho DB, Turchi Martelli CM, et al. (2019-01-01). "ZikaPLAN: addressing the knowledge gaps and working towards a research preparedness network in the Americas". Global Health Action. 12 (1): 1666566. doi:10.1080/16549716.2019.1666566. PMC 6818126. PMID 31640505.
  28. ^ "PAHO/WHO | Malaria Technical Advisory Group - Current Members". Pan American Health Organization / World Health Organization. 2019-05-25. Retrieved 2021-04-06.{{cite web}}: CS1 maint: url-status (link)
  29. ^ "Dr Lyda Osorio | Infectious Diseases Data Observatory". www.iddo.org. Retrieved 2021-04-13.
  30. ^ "Editorial Board". BMJ Global Health. Retrieved 2021-04-06.
  31. ^ Gobernación del Valle del Cauca. "Por su trabajo investigativo y aporte a la salud para contrarrestar el Coronavirus, la Gobernación condecoró a cuatro médicos de la región". www.valledelcauca.gov.co (in Spanish). Retrieved 2021-04-07.{{cite web}}: CS1 maint: url-status (link)
  32. ^ "Women scientists capture public attention as COVID-19 rages across the world". www.who.int. Retrieved 2021-04-06.

External links

Lyda Osorio - Workshop Internacional sobre Vírus Zika - Fiocruz PE (in English)

Universidad del Valle. Salud Pública en Tiempos de Pandemia: Respuesta interdisciplinaria sobre el COVID-19 [en Colombia] (in Spanish)

Centro Internacional de Entrenamiento e Investigaciones Médicas (CIDEIM)

Retrieved from "https://en.wikipedia.org/w/index.php?title=Lyda_Osorio&oldid=1017995803"